ReviewMolecular biology reports2026
Research progress on ferroptosis in drug-induced kidney injury.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ferroptosis is a novel form of programmed cell death that has garnered increasing attention in recent years in the study of drug-induced kidney injury, where it plays a critical role in the onset and progression of the disease. This review systematically summarizes the core mechanisms and regulatory pathways of ferroptosis in kidney injury, as well as the crosstalk between ferroptosis and other forms of programmed cell death. It further discusses how microbial-derived drugs, traditional Chinese medicines, and their active monomers induce renal ferroptosis through their respective core targets, thereby mediating drug-induced kidney injury. By synthesizing existing evidence, this paper clarifies the common patterns and key targets by which various drugs induce kidney injury via the ferroptosis pathway. It provides a theoretical foundation for drug safety evaluation, clinical medication risk early warning and targeted renal protection strategies, and also sheds new light on the exploration of combined medication schemes, indirect toxic mechanisms and individualized toxicity detection.
Indexed as
Identifiers
43007468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.